CAR T cell therapies to promote drug-free remission in lupus care
BMS’s CC-97540 and Cabaletta Bio’s CABA-201 highlight CAR T’s potential to achieve lasting drug-free remission, marking a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CAR-T Therapy
AstraZeneca to acquire Gracell Biotechnologies
Deal includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and…
US FDA approves Gilead cell therapy for earlier lymphoma
The one-time treatment was initially approved in 2017 for patients with large B-cell lymphoma who did not respond to at least two…
US FDA approves cancer therapy by Johnson & Johnson and Legend Biotech
The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell…